Insulin aspart biosimilar (Nanjing Hanxin Pharm)
门冬胰岛素生物类似药（南京汉欣）
Report date: 2023/03/08 16:39:52
Base Information
Drug NameInsulin aspart biosimilar (Nanjing Hanxin Pharm)
Drug Alias NameN/A
Classification
Mechanisms of Action
Targets
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/Territory
CombinationsNo
Global Highest StatusIND
Highest Status in ChinaIND
Originator CompaniesNanjing Hanxin Pharmacceutical Tech Co Ltd
China Registration ClassN/A
Develop Information
Active CompaniesNanjing Hanxin Pharmacceutical Tech Co Ltd
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A
Other Information
ATC CodeN/A
Related LinksN/A